Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma
Status:
Terminated
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/II open-label, dose-escalating study in patients with metastatic colorectal
cancer. The objectives of the study are to obtain information on the safety of radiolabeled
IDEC-159, as well as its activity in colorectal cancer. Another objective is to determine the
maximum tolerated dose (MTD). The study duration is 2 years with visits occuring daily and/or
weekly for the first 3 months, and every 6 weeks until the end of the 2 year period.